Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosfluridine tidoxil

Drug Profile

Fosfluridine tidoxil

Alternative Names: Fosfluridine; HDP 99.0006; HDP 990006

Latest Information Update: 13 Oct 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heidelberg Pharma
  • Developer Heidelberg Pharma Research
  • Class Antineoplastics; Pyrimidine nucleosides
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Actinic keratosis; Breast cancer; Colorectal cancer

Most Recent Events

  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 28 Feb 2011 Heidelberg Pharma has been acquired by Wilex
  • 15 Nov 2010 Suspended - Phase-II for Actinic keratosis in Germany (PO) before November 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top